Orlistat therapy of young patients with hypothalamic obesity

Abstract

Thirty patients with hypothalamic obesity (HO) aged 18-29years were examined in order to evaluate the effect of orlistat on body weight and hormonal metabolic disorders and the tolerance of this agent in patients with HO. The duration of orlistat therapy was 6 months; the treatment was paralleled by low-caloric diet. Anthropometric parameters, arterial pressure, carbohydrate and lipid metabolism values, and insulin resistance index were evaluated initially and after 1, 3, and 6 months of treatment. Positive changes in arterial pressure and all anthropometric parameters, including those characterizing abdominal obesity, normalization of basal insulinemia, decrease of stimulated insulinemia, increase of insulin resistance, improvement of lipid spectrum of the blood with leveling of atherogenic shifts were observed during the treatment. Hence, the results demonstrated high efficiency of orlistat therapy in patients with HO.